Common genetic variants do not impact clinical prediction of methotrexate treatment outcomes in early rheumatoid arthritis
Journal of Internal Medicine · 2025
DOI: 10.1111/joim.20087 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Internal Medicine, 2025. Verfasst von Anton Öberg Sysojev und 10 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Methotrexate, Arthritis, Rheumatoid, Antirheumatic Agents, Genetic Variation. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancerfonden, Hjärt-Lungfonden, Karolinska Institutet.
Abstract (Originalsprache)
Background
Methotrexate (MTX) is the mainstay initial treatment of rheumatoid arthritis (RA), but individual response varies and remains difficult to predict. The role of genetics remains unclear, but studies suggest its importance.
Methods
Incident RA patients starting MTX‐monotherapy were identified through a large‐scale Swedish register linkage. Demographic, clinical, medical, and drug history features were combined with fully imputed genotype data and used to train and evaluate multiple learning models to predict key MTX treatment outcomes.
Results
Among 2432 patients, we consistently observed an estimated area under the curve (AUC) of ∼0.62, outperforming models trained on sex and age. The best performance was observed for EULAR primary response (AUC = 0.67), whereas models struggled the most with predicting discontinuation. Genetics provided negligible improvements to prediction quality.
Conclusions
Despite an extensive study population with broad multi‐modal data, predicting MTX treatment outcomes remains a challenge. Common genetic variants added minimal predictive power over clinical features.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Institute of Environmental Medicine (IMM), Karolinska Institutet, Stockholm, Sweden.
- Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.
- Center for Molecular Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
- Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland.
- MedTechLabs, BioClinicum, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Anton Öberg Sysojev, Lars Klareskog, Helga Westerlind
Förderung
- Cancerfonden
- Hjärt-Lungfonden
- Karolinska Institutet
- Nordforsk
- Reumatikerförbundet
- Stiftelsen Konung Gustaf V:s 80-årsfond
- Stiftelsen Professor Nanna Svartz Fond
- Vinnova
Zitieren
APA
Sysojev, A. Ö., Delcoigne, B., Frisell, T., Alfredsson, L., Klareskog, L., SRQ biobank group, Saevarsdottir, S., Boman, M., Padyukov, L., Askling, J., & Westerlind, H. (2025). Common genetic variants do not impact clinical prediction of methotrexate treatment outcomes in early rheumatoid arthritis. Journal of Internal Medicine. https://doi.org/10.1111/joim.20087
Vancouver
Sysojev AÖ, Delcoigne B, Frisell T, Alfredsson L, Klareskog L, SRQ biobank group, et al. Common genetic variants do not impact clinical prediction of methotrexate treatment outcomes in early rheumatoid arthritis. Journal of Internal Medicine. 2025. doi:10.1111/joim.20087
BibTeX
@article{Sysojev2025,
author = {Sysojev, Anton Öberg and Delcoigne, Bénédicte and Frisell, Thomas and Alfredsson, Lars and Klareskog, Lars and SRQ biobank group, SRQ biobank group and Saevarsdottir, Saedis and Boman, Magnus and Padyukov, Leonid and Askling, Johan and Westerlind, Helga},
title = {Common genetic variants do not impact clinical prediction of methotrexate treatment outcomes in early rheumatoid arthritis},
journal = {Journal of Internal Medicine},
year = {2025},
doi = {10.1111/joim.20087}
}
EUVIMED